DAFNA Capital's recent SEC filing reveals changes in ETF holdings.
The adjustments reflect a strategic shift in their biotech portfolio.
iShares Biotechnology ETF remains a key component of their investments.
Briefing: DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
Strategic angle: DAFNA Capital has made adjustments to its holdings in the iShares Biotechnology ETF as part of a broader strategy in the biotech sector.